399 related articles for article (PubMed ID: 1733228)
21. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
Dorr RT; Liddil JD; Soble MJ
Invest New Drugs; 1986; 4(4):305-13. PubMed ID: 3583642
[TBL] [Abstract][Full Text] [Related]
22. Buthionine sulfoximine spares intracellular glutamate: a possible mechanism for cell growth stimulation.
Kang YJ
Cell Mol Biol Res; 1993; 39(7):675-84. PubMed ID: 8055000
[TBL] [Abstract][Full Text] [Related]
23. Depletion of intracellular GSH and NPSH by buthionine sulfoximine and diethyl maleate: factors that influence enhancement of aerobic radiation response.
Varnes ME; Biaglow JE; Roizin-Towle L; Hall EJ
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1229-33. PubMed ID: 6469743
[TBL] [Abstract][Full Text] [Related]
24. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono K; Shrieve DC
J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
[TBL] [Abstract][Full Text] [Related]
25. Effect of modulators of glutathione synthesis on the hepatotoxicity of 2-methylfuran.
Ravindranath V; Boyd MR
Biochem Pharmacol; 1991 May; 41(9):1311-8. PubMed ID: 2018563
[TBL] [Abstract][Full Text] [Related]
26. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
Hansson J; Edgren M; Ehrsson H; Ringborg U; Nilsson B
Cancer Res; 1988 Jan; 48(1):19-26. PubMed ID: 3334994
[TBL] [Abstract][Full Text] [Related]
27. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
28. Toxic effects of extended glutathione depletion by buthionine sulfoximine on murine mammary carcinoma cells.
Dethlefsen LA; Biaglow JE; Peck VM; Ridinger DN
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1157-60. PubMed ID: 3744934
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
Kable EP; Favier D; Parsons PG
Cancer Res; 1989 May; 49(9):2327-31. PubMed ID: 2706620
[TBL] [Abstract][Full Text] [Related]
30. Depletion of glutathione after gamma irradiation modifies survival.
Saunders EL; Meredith MJ; Eisert DR; Freeman ML
Radiat Res; 1991 Mar; 125(3):267-76. PubMed ID: 2000450
[TBL] [Abstract][Full Text] [Related]
31. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase.
Messina JP; Lawrence DA
J Immunol; 1989 Sep; 143(6):1974-81. PubMed ID: 2789253
[TBL] [Abstract][Full Text] [Related]
32. The effect of in utero administration of buthionine sulfoximine on rat development.
Reyes E; Ott S; Robinson B; Contreras R
Pharmacol Biochem Behav; 1995 Apr; 50(4):491-7. PubMed ID: 7617692
[TBL] [Abstract][Full Text] [Related]
33. Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine.
Lee FY; Allalunis-Turner MJ; Siemann DW
Br J Cancer; 1987 Jul; 56(1):33-8. PubMed ID: 3620316
[TBL] [Abstract][Full Text] [Related]
34. Effects of the long-term depletion of reduced glutathione in mice administered L-buthionine-S,R-sulfoximine.
Sun JD; Ragsdale SS; Benson JM; Henderson RF
Fundam Appl Toxicol; 1985 Oct; 5(5):913-9. PubMed ID: 2866140
[TBL] [Abstract][Full Text] [Related]
35. Glutathione depletion, radiosensitization, and misonidazole potentiation in hypoxic Chinese hamster ovary cells by buthionine sulfoximine.
Clark EP; Epp ER; Biaglow JE; Morse-Gaudio M; Zachgo E
Radiat Res; 1984 May; 98(2):370-80. PubMed ID: 6539482
[TBL] [Abstract][Full Text] [Related]
36. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs.
Thrall BD; Raha GA; Springer DL; Meadows GG
Pigment Cell Res; 1991 Dec; 4(5-6):234-9. PubMed ID: 1823927
[TBL] [Abstract][Full Text] [Related]
37. Tissue-specific changes in glutathione and cysteine after buthionine sulfoximine treatment of rats and the potential for artifacts in thiol levels resulting from tissue preparation.
Standeven AM; Wetterhahn KE
Toxicol Appl Pharmacol; 1991 Feb; 107(2):269-84. PubMed ID: 1994510
[TBL] [Abstract][Full Text] [Related]
38. The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation.
Drew R; Miners JO
Biochem Pharmacol; 1984 Oct; 33(19):2989-94. PubMed ID: 6148944
[TBL] [Abstract][Full Text] [Related]
39. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
Xu BH; Gupta V; Singh SV
Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448
[TBL] [Abstract][Full Text] [Related]
40. Promotion of trans-platinum in vivo effects on renal heme and hemoprotein metabolism by D,L-buthionine-S,R-sulfoximine. Possible role of glutathione.
Mayer RD; Maines MD
Biochem Pharmacol; 1990 May; 39(10):1565-71. PubMed ID: 2337413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
